A B O U T  U S

The Applanta team comes from a rich mix of backgrounds with a passion for innovation and common focus on  quality in the design and development of mobile apps.  


Jay Yadav small

Dr. Jay S. Yadav, M.D., is the co-founder of Applanta, LLC. He is also the founder and CEO of CardioMEMS and ICON Interventional Systems®. He is also a consulting cardiologist at the Piedmont Heart Institute. He was the founder of Angioguard (acquired by JNJ) and initial investor and director of SMART Therapeutics (acquired by Boston Scientific). Dr. Yadav is a director of several private medical device and technology companies. He is a member of the Metro Atlanta Bioscience Leadership Council and the American Heart Association; and a Director of Georgia Bio and The Indus Entrepreneurs. Dr. Yadav has authored two books and over two hundred publications and has received numerous honors including the AHA Top Ten Scientific Advances for 2003, Ellis Island Medal of Honor for 2004, Southeast Medical Device Association Entrepreneur of the Year Award for 2010 and Ernst and Young Entrepreneur of the Year for Healthcare (Southern Region) for 2011. For more go to:


3e64edd6b7148c6eb5442b18329481e6 (1)
Doriano Carta is the co-founder of Applanta, LLC. Doriano has written as a tech journalist for some of the most reputable technical resources such as Mashable.comGigaOm.comAppolicious and others. Samples of his published articles can be found here:
Doriano has worked in Information Technology for firms such as CardioMEMS, CompuCom, MAG Mutual, Fidelity Bank and several firms in the Medical Device industry. For more information go to or his twitter account @Paisano


PI Roth2_0

Noah Roth is our legal counsel.  Noah has over 15 year’s experience in the development of innovative products and developing effective IP strategies. He has worked as a leader in technology development for Micro therapeutics, Johnson & Johnson and ICON Interventional Systems.  He brings a depth of knowledge in Intellectual Property, Development Strategies and Regulatory Considerations.

Visit Us On TwitterVisit Us On FacebookVisit Us On Google PlusCheck Our Feed